Iferanserin has been investigated for the treatment of Hemorrhoids.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Hydrocodone | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Magnesium sulfate | The therapeutic efficacy of Iferanserin can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Iferanserin may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Mirtazapine | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Orphenadrine | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Pramipexole | Iferanserin may increase the sedative activities of Pramipexole. |
| Ropinirole | Iferanserin may increase the sedative activities of Ropinirole. |
| Rotigotine | Iferanserin may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Iferanserin. |
| Sodium oxybate | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Thalidomide | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Iferanserin. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Iferanserin is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Iferanserin is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Iferanserin is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Iferanserin is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Iferanserin is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Iferanserin is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Iferanserin is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Iferanserin is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Iferanserin is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Iferanserin is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Iferanserin is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Iferanserin is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Iferanserin is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Iferanserin is combined with (S)-Warfarin. |
| Ethanol | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Iferanserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Iferanserin is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Iferanserin is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Iferanserin is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Iferanserin is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Iferanserin is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Iferanserin is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Iferanserin is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Iferanserin is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Iferanserin is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Iferanserin is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Iferanserin is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Iferanserin is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Iferanserin is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Iferanserin is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Iferanserin is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Iferanserin is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Iferanserin is combined with Alaproclate. |
| Zopiclone | The risk or severity of adverse effects can be increased when Iferanserin is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Iferanserin. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Iferanserin. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Iferanserin. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Iferanserin. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Iferanserin. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Iferanserin. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Iferanserin. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Iferanserin. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Iferanserin. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Iferanserin. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Iferanserin. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Iferanserin. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Iferanserin. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Iferanserin. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Iferanserin. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Iferanserin. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Iferanserin. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Iferanserin. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Iferanserin. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Iferanserin. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Iferanserin. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Iferanserin. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Iferanserin. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Iferanserin. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Iferanserin. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Iferanserin. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Iferanserin. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Iferanserin. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Iferanserin. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Iferanserin. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Iferanserin. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Iferanserin. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Iferanserin. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Iferanserin. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Iferanserin. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Iferanserin. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Iferanserin. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Iferanserin. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with Iferanserin. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Iferanserin. |